Figure 2
TG2-knocked-down breast and ovarian cancer cells secreted less IL-6. (a) MDA-MB-231 human breast cancer cells were stably transfected with shRNAs targeting TG2. The efficiency of knockdown was assessed with Western blot. (b) IL-6 levels in the culture supernatants of control and TG2-knocked-down MDA-MB-231 cells were determined with ELISA. (c) Effect of the TG2 inhibitor cysteamine (CyM) on IL-6 secretion in control MDA-MB-231 cells was determined with ELISA. (d) MDA-MB-231 cells were stably transfected with shRNAs targeting IL-6. The efficiency of knockdown was verified by measuring IL-6 levels in the culture supernatants. TG2 expression of control and IL-6-knocked-down MDA-MB-231 cells was analyzed with Western blot. (b-d) 1 × 104 cells were applied on 24-well plates and allowed to adhere overnight. Then the medium was replaced, and cells were permitted to grow for 24 or 48 h (b, c) or for 48 h only (d). Data represent mean ± SD, based on three independent experiments using samples from triplicate cell cultures. IL-6, interleukin 6; SD, standard deviation; TG2, transglutaminase 2.